Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial

Journal:

The Lancet Oncology

Published:

2025-06-14

DOI:

10.1016/s1470-2045(25)00209-8

Affiliations:

20

Authors:

22

Go to article

Institutions	Authors	Share
Exelixis, United States of America (USA)	4.000000	0.18
Roche, Switzerland	1.000000	0.05
Ambulatorium Chemioterapii, Poland	1.000000	0.05
Hospital of the University of Montreal (CHUM), Canada	1.000000	0.05
Cross Cancer Institute, AHS, Canada	1.000000	0.05
Peter MacCallum Cancer Centre (Peter Mac), Australia	1.000000	0.05
Georges Pompidou European Hospital (HEGP), France	1.000000	0.05
Metropolitan General Hospital, Greece	1.000000	0.05
Dnipro State Medical University (DSMU), Ukraine	1.000000	0.05
Hospital Israelita Albert Einstein, Brazil	1.000000	0.05
Athens Medical Center, Greece	1.000000	0.05
Vall d'Hebron University Hospital (HUVH), ICS, Spain	1.000000	0.05
Organización Médica de Investigación (OMI), Argentina	1.000000	0.05
University Medical Center Schleswig-Holstein - Campus Lübeck (UKSH Lübeck), Germany	1.000000	0.05
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	1.000000	0.05
City of Hope Comprehensive Cancer Center, United States of America (USA)	1.000000	0.05
Huntsman Cancer Institute at the University of Utah (HCI), Utah, United States of America (USA)	1.000000	0.05
National Cancer Center Hospital East, Japan	1.000000	0.05
Careggi University Hospital (AOUC), UNIFI, Italy	0.500000	0.02
University of Florence (UNIFI), Italy	0.500000	0.02

Interested in Oncology and Carcinogenesis?